Journal of Ocular Pharmacology and Therapeutics最新文献

Rosalind Franklin Society Proudly Announces the 2024 Award Recipient for Journal of Ocular Pharmacology and Therapeutics. 罗莎琳德·富兰克林协会自豪地宣布了2024年眼科药理学和治疗学杂志的获奖者。

IF 1.9 4区医学

Journal of Ocular Pharmacology and Therapeutics Pub Date : 2025-06-01 DOI: 10.1089/jop.2024.0046.rfs2024

Katie Dolan

引用次数: 0

Effect of Chemical Injury on Autophagy in Canine Corneal Stromal Fibroblasts. 化学损伤对犬角膜间质成纤维细胞自噬的影响。

IF 1.9 4区医学

Journal of Ocular Pharmacology and Therapeutics Pub Date : 2025-06-01 Epub Date: 2025-02-17 DOI: 10.1089/jop.2024.0211

Brayden L Routh, Ratnakar Tripathi, Elizabeth A Giuliano, Brenden R Lankau, Prashant R Sinha, Rajiv R Mohan

{"title":"Effect of Chemical Injury on Autophagy in Canine Corneal Stromal Fibroblasts.","authors":"Brayden L Routh, Ratnakar Tripathi, Elizabeth A Giuliano, Brenden R Lankau, Prashant R Sinha, Rajiv R Mohan","doi":"10.1089/jop.2024.0211","DOIUrl":"10.1089/jop.2024.0211","url":null,"abstract":"Purpose: Ocular trauma leads to loss of corneal clarity resulting in vision deficits. Autophagy plays a critical role in the extracellular matrix, tissue repair, and homeostasis but its precise mechanistic role in regulating corneal function remains unknown. The present study investigated the modulation of autophagy-related genes (LC3, Beclin1, Sqstm1/p62, and Lamp1) in healthy and injured canine corneal stromal fibroblasts (CSFs). Methods: Primary CSFs were generated from healthy donor canine corneas and grown in minimum essential medium. Following incubation, cultures were exposed to nitrogen mustard (NM) and subjected to an autophagy activator, rapamycin (R), or vehicle treatment. Phase-contrast microscopy, quantitative reverse transcription polymerase chain reaction (qRT-PCR), and immunofluorescence staining were used to study the role of autophagy genes in canine corneal wound healing in vitro. Results: Phase-contrast microscopy showed that NM exposure led to morphological changes with stress fibers in CSFs, which was noticeably decreased by rapamycin treatment. Treatment of CSFs with rapamycin alone showed fibroblast hypertrophy while vehicle-treated population of CSFs exhibited typical spindle morphology. The qRT-PCR showed increased expression of LC3, Beclin1, and Lamp1 mRNA when treated with NM, NM+R, and R in comparison to vehicle-treated CSFs. Sqstm1/p62 expression was upregulated in the NM and NM+R treatment groups but was reduced in the R-treated group. Immunofluorescence showed similar results of the protein levels. Conclusions: This study suggests that autophagy is an essential component in corneal healing post-injury. Further, results suggest that targeting autophagy may offer an attractive treatment option to reestablish corneal clarity following ocular insult.","PeriodicalId":16689,"journal":{"name":"Journal of Ocular Pharmacology and Therapeutics","volume":" ","pages":"266-274"},"PeriodicalIF":1.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143441279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Topical Losartan in the Management of Corneal Scarring Fibrosis: Update on Dosage, Efficacy, and Potential Epithelial Toxicity. 局部氯沙坦治疗角膜瘢痕性纤维化：剂量、疗效和潜在上皮毒性的最新进展。

IF 1.9 4区医学

Journal of Ocular Pharmacology and Therapeutics Pub Date : 2025-06-01 Epub Date: 2025-04-16 DOI: 10.1089/jop.2024.0200

Barbara A L Dutra, Steven E Wilson

{"title":"Topical Losartan in the Management of Corneal Scarring Fibrosis: Update on Dosage, Efficacy, and Potential Epithelial Toxicity.","authors":"Barbara A L Dutra, Steven E Wilson","doi":"10.1089/jop.2024.0200","DOIUrl":"10.1089/jop.2024.0200","url":null,"abstract":"Losartan is an angiotensin II receptor blocker (ARB) that also inhibits transforming growth factor (TGF)-beta signaling by blocking the activation of extracellular signal-regulated kinase (ERK) in the noncanonical TGF-beta signaling pathway. Rabbit studies demonstrated the efficacy of topical losartan in reducing fibrotic scarring following a variety of corneal injuries, such as descemetorhexis, alkali burns, and photorefractive keratectomy (PRK). Several human case reports have subsequently shown the efficacy of topical losartan in treating scarring fibrosis resulting from surgical complications and infections. Since rabbit studies have also found concentration-dependent corneal epithelial toxicity associated with topical losartan, a lower concentration of 0.2 mg/mL administered 6 times daily is recommended in corneas with epithelial defects until epithelial closure is achieved before using standard 0.8 mg/mL losartan 6 times a day for the duration of treatment. For eyes with intact epithelium, a dose of 0.8 mg/mL 6 times daily is recommended throughout the treatment period. Doses of topical losartan above 0.8 mg/mL should be avoided due to dosage-related increases in persistent epithelial defects. Clinical studies are needed to further assess questions such as which corneal fibrotic disorders are most likely to respond to topical losartan treatment and whether a lower frequency of application leads to greater treatment failure.","PeriodicalId":16689,"journal":{"name":"Journal of Ocular Pharmacology and Therapeutics","volume":" ","pages":"232-236"},"PeriodicalIF":1.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144004729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tacrolimus 0.1% Ophthalmic Suspension: Corneal and Intraocular Penetration Study. 0.1%他克莫司眼用混悬液：角膜和眼内渗透研究。

IF 1.9 4区医学

Journal of Ocular Pharmacology and Therapeutics Pub Date : 2025-06-01 Epub Date: 2025-04-18 DOI: 10.1089/jop.2024.0165

Maxime Quirke, Fabien Lamoureux, Christophe Arnoult, Gladys Gress, Ariella Ganem, Théophile Charpentier, Marc Muraine, Julie Gueudry

{"title":"Tacrolimus 0.1% Ophthalmic Suspension: Corneal and Intraocular Penetration Study.","authors":"Maxime Quirke, Fabien Lamoureux, Christophe Arnoult, Gladys Gress, Ariella Ganem, Théophile Charpentier, Marc Muraine, Julie Gueudry","doi":"10.1089/jop.2024.0165","DOIUrl":"10.1089/jop.2024.0165","url":null,"abstract":"Purpose: Topical tacrolimus is currently used in ocular surface pathologies as a corticosteroid-sparing immunosuppressive agent. It could also help prevent endothelial corneal graft rejection and inflammatory diseases; however, its hydrophobic nature and high molecular weight theoretically limit its intraocular penetration. The aim of this study is to investigate the corneal and intraocular penetration of a 0.1% tacrolimus ophthalmic suspension. Methods: Sixteen rabbits were randomly spread into four groups defined by the delay between the last tacrolimus instillation and corneal sampling (2, 6, 11, and 24 h). Three rabbits per group received bilateral instillations of tacrolimus twice daily for 5 days, the 4th subject in each group serving as negative controls. The 5th day, conjunctiva, corneal epithelium, anterior stroma, posterior stroma, corneal endothelium, iris, choroid/retina, aqueous humor, and plasma samples were collected. Tacrolimus concentrations were determined using high-performance liquid chromatography coupled with tandem mass spectrometry. Results: Maximum mean concentration was reached after 2 h in the epithelium, anterior and posterior stroma, and endothelium: 12794 (±2656), 436 (±178), 341 (±179), and 4125 (±1673) ng/g, respectively. The descending rank order of exposure over 24 h was: corneal epithelium; corneal endothelium; conjunctiva; anterior stroma; posterior stroma; iris; and chorioretina with 158.0; 39.99; 4.620; 4.134; 3.350; 0.384; 0.270 ng.h/mg, respectively. Conclusions: Tacrolimus concentrations measured in the corneal tissues are significantly higher than that described as lower limit of efficacy in solid organ transplantation. Topical 0.1% tacrolimus could therefore become an alternative to corticosteroids for endothelial graft rejection prevention and endothelial inflammatory pathologies management.","PeriodicalId":16689,"journal":{"name":"Journal of Ocular Pharmacology and Therapeutics","volume":" ","pages":"275-280"},"PeriodicalIF":1.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Myopia Progression Study Comparing Low-Dose (0.01%) Atropine Eye Drops with a Control Group. 低剂量（0.01%）阿托品滴眼液与对照组近视进展的比较研究。

IF 1.9 4区医学

Journal of Ocular Pharmacology and Therapeutics Pub Date : 2025-06-01 Epub Date: 2025-04-18 DOI: 10.1089/jop.2024.0202

Hortensia Sanchez-Tocino, Ana Villanueva Gomez, Rebeca Saldaña Burgos, Magda Massae Hata Viveiros, Alicia Galindo-Ferreiro

{"title":"Myopia Progression Study Comparing Low-Dose (0.01%) Atropine Eye Drops with a Control Group.","authors":"Hortensia Sanchez-Tocino, Ana Villanueva Gomez, Rebeca Saldaña Burgos, Magda Massae Hata Viveiros, Alicia Galindo-Ferreiro","doi":"10.1089/jop.2024.0202","DOIUrl":"10.1089/jop.2024.0202","url":null,"abstract":"Purpose: To evaluate myopia progression in children treated with 0.01% atropine eye drops compared with controls. Methods: Two longitudinal cohorts of myopic children (atropine and control) were observed in different time periods. All children had an increase in myopia of greater than -0.50 diopters (D) or axial length (AL) growth of >0.20 mm in the previous year. Patients were examined at baseline and every 6 months for 18 months. The primary outcomes were the annual progression rate of spherical equivalent refractive error (SER) and AL. Response to treatment was categorized as insufficient, moderate, or good. Progression according to age was also evaluated. Statistical significance was defined as P < 0.05. Results: The study included 243 myopic children [127 (44.7%) female; mean age, 10.19 ± 2.29 years]. The atropine group comprised 158 (65%) children. At 18 months, the mean (95% confidence interval) change in SER was -0.85 D (-1.00, -0.69) in the control group and -0.73 D (-0.85, -0.61) in atropine (p = 0.295). The mean increase in AL was 0.41 mm (0.32, 0.50) in the control group and 0.33 mm (0.28, 0.39) in the atropine (p = 0.160). Children aged <9 years had the lowest percentage of success [3/21 (27.8%)] in the atropine group and the highest percentage of failure (63.2%) (p = 0.03). Conclusion: Atropine drops at 0.01% did not slow myopia progression. Increasing the concentration or combining with optical treatments may be necessary, particularly for children aged <9 years, who showed the greatest progression but also had the highest potential for myopia control.","PeriodicalId":16689,"journal":{"name":"Journal of Ocular Pharmacology and Therapeutics","volume":" ","pages":"244-250"},"PeriodicalIF":1.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144015313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Medicare Part D Glaucoma Drug Prescribing Patterns by Ophthalmologists from 2018 to 2022. 2018年至2022年眼科医生的医疗保险D部分青光眼药物处方模式。

IF 1.9 4区医学

Journal of Ocular Pharmacology and Therapeutics Pub Date : 2025-06-01 Epub Date: 2025-02-05 DOI: 10.1089/jop.2024.0196

Rita Vought, Victoria Vought, Alexander B Crane, Albert S Khouri

{"title":"Medicare Part D Glaucoma Drug Prescribing Patterns by Ophthalmologists from 2018 to 2022.","authors":"Rita Vought, Victoria Vought, Alexander B Crane, Albert S Khouri","doi":"10.1089/jop.2024.0196","DOIUrl":"10.1089/jop.2024.0196","url":null,"abstract":"Background: Glaucoma is a chronic, progressive disease of visual loss and blindness that is often managed pharmacologically. The objective of this study was to evaluate glaucoma drug prescribing trends by ophthalmologists in the United States from 2018 to 2022. Methods: Data on ophthalmologist prescribers were abstracted from Medicare Part D Prescriber Public Use Files to identify the total number of claims for each drug. Drugs were classified by type (generic or brand-name) and by drug class (carbonic anhydrase inhibitors, alpha-2 agonists, beta-blockers, prostaglandin analogs, rho kinase inhibitors, parasympathomimetic drugs, and mixed-mechanism drugs). The types of drugs prescribed were compared longitudinally. Results: Forty glaucoma drugs were prescribed under Medicare Part D from July 1st, 2018, to June 30th, 2022. A dip in total claims and claims by drug class was observed from 2018-2019 to 2019-2020. This was followed by increases to the greater number of claims in 2021-2022. Prostaglandin analogues were the most frequently prescribed class, and the most commonly prescribed drugs were latanoprost, timolol, and the dorzolamide/timolol combination. The majority of claims consisted of generics, and this value increased longitudinally as well. The most rapidly growing class prescribed by physicians was rho kinase inhibitors. Conclusion: Longitudinal differences in Medicare Part D glaucoma drug claims may reflect changing practice patterns and preferences among providers. An increasing number of claims annually, with the exception of the COVID-19 pandemic onset, reflects the growing prevalence of glaucoma. The utilization of new glaucoma agents, such as rho kinase inhibitors, is rapidly increasing as a new therapeutic option.","PeriodicalId":16689,"journal":{"name":"Journal of Ocular Pharmacology and Therapeutics","volume":" ","pages":"259-265"},"PeriodicalIF":1.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143256064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Eyes on New Product Development. 关注新产品开发。

IF 1.9 4区医学

Journal of Ocular Pharmacology and Therapeutics Pub Date : 2025-06-01 Epub Date: 2025-04-28 DOI: 10.1089/jop.2025.0097

Gary D Novack

引用次数: 0

Durability of Treatment with a Thermomechanical Device in Meibomian Gland Dysfunction: An Observational Extension Study. 热机械装置治疗睑板腺功能障碍的持久性：一项观察性扩展研究。

IF 1.9 4区医学

Journal of Ocular Pharmacology and Therapeutics Pub Date : 2025-06-01 Epub Date: 2025-04-16 DOI: 10.1089/jop.2025.0033

Ehsan Sadri, Anthony Verachtert, Gregory D Parkhurst, Julio Echegoyen, Ifat Klein, Yael Agmon Gerstein, Gregg J Berdy

{"title":"Durability of Treatment with a Thermomechanical Device in Meibomian Gland Dysfunction: An Observational Extension Study.","authors":"Ehsan Sadri, Anthony Verachtert, Gregory D Parkhurst, Julio Echegoyen, Ifat Klein, Yael Agmon Gerstein, Gregg J Berdy","doi":"10.1089/jop.2025.0033","DOIUrl":"10.1089/jop.2025.0033","url":null,"abstract":"Purpose: To evaluate the durability of thermomechanical device treatment effect in patients with meibomian gland dysfunction (MGD) at 6 months post-treatment. Methods: This was an extension of an initial 3-month, prospective, controlled, randomized, masked, multicenter pivotal study, in which subjects with MGD were randomized to thermomechanical device treatment (3 sessions, 2 weeks apart) or a single control treatment. The extension study was a single-arm, observational study in the same 5 sites of the pivotal study. A subset of subjects from the thermomechanical device group with an increase in tear break-up time (TBUT) of 2.5 s or greater in at least 1 eye at 1- or 3-month follow-up and able to attend the 6-month follow-up were included. Effectiveness endpoints included changes in TBUT, Meibomian gland score (MGS), and Ocular Surface Disease Index (OSDI) from baseline to 6 months. Device-related adverse events (AEs) were also assessed. Results: At 6 months post-treatment, 21 subjects (42 eyes) demonstrated significant improvements from baseline in mean TBUT (5.2 ± 3.8 s; P < 0.001), mean MGS (18.2 ± 10.9; P < 0.0001), and mean OSDI (-24.3 ± 26.5; P = 0.0004). Improvements in corneal staining scores were also observed. No ocular AEs were reported. Conclusions: The findings of the extension study demonstrate that the clinical benefit of the thermomechanical device, evaluated by TBUT, MGS, and OSDI, can be maintained out to 6 months and that the device is safe and effective in improving the signs and symptoms of evaporative dry eye disease in MGD.","PeriodicalId":16689,"journal":{"name":"Journal of Ocular Pharmacology and Therapeutics","volume":" ","pages":"237-243"},"PeriodicalIF":1.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biodistribution of Reconstituted High-Density Lipoprotein Nanoparticles for Targeted Delivery to Retinal Ganglion Cells. 用于视网膜神经节细胞靶向递送的高密度脂蛋白纳米颗粒的生物分布。

IF 1.9 4区医学

Journal of Ocular Pharmacology and Therapeutics Pub Date : 2025-06-01 Epub Date: 2025-04-18 DOI: 10.1089/jop.2024.0191

R Max Petty, Rajiv S Rangan, Stacy Curry, Calvin D Brooks, Nirupama Sabnis, Abbot F Clark, Andras G Lacko, Raghu R Krishnamoorthy

{"title":"Biodistribution of Reconstituted High-Density Lipoprotein Nanoparticles for Targeted Delivery to Retinal Ganglion Cells.","authors":"R Max Petty, Rajiv S Rangan, Stacy Curry, Calvin D Brooks, Nirupama Sabnis, Abbot F Clark, Andras G Lacko, Raghu R Krishnamoorthy","doi":"10.1089/jop.2024.0191","DOIUrl":"10.1089/jop.2024.0191","url":null,"abstract":"Purpose: Nanoparticle-based drug delivery systems offer a promising approach for overcoming the challenges of ocular drug delivery. Our study evaluated the biodistribution and potential targeting of reconstituted high-density lipoprotein nanoparticles (rHDL NPs) loaded with near-infrared dye IR780 to retinal ganglion cells (RGCs) and optic nerve head astrocytes (ONHAs) as a model for neuroprotective drug delivery in glaucoma. Methods: A stable rHDL-payload complex was formulated using IR780, phosphatidylcholine, and apolipoprotein A-I (Apo A-I) by using a novel preparation method. Fluorescent rHDL (rHDL-IR780) was assessed for cellular uptake in primary human ONHAs in vitro, whereas scavenger receptor class B1 (SR-B1) expression was confirmed by Western blot. Receptor-mediated uptake was examined by SR-B1 receptor blocking. Ex vivo biodistribution was evaluated by intravitreal injection of rHDL into postmortem human donor eyes. Results: Spectroscopic analysis confirmed IR780 encapsulation in rHDL NPs. Blocking SR-B1 receptors significantly reduced IR780 uptake by ONHAs, supporting an SR-B1-mediated delivery mechanism, in addition to confirming SR-B1 expression in human retinal lysates. In ex vivo experiments, 4 h postinjection, IR780 localized in the retinal nerve fiber and ganglion cell layers. By 24 h, IR780 penetrated deeper retinal layers, achieving RGC uptake. Conclusions: Our findings demonstrate that rHDL NPs facilitate targeted delivery to retinal tissues through an Apo A-I/SR-B1 pathway, overcoming ocular barriers to reach RGCs. This study supports the potential of rHDL NPs as a platform for neuroprotective drug delivery to treat glaucoma, enhancing both pharmacokinetics and targeted cellular uptake.","PeriodicalId":16689,"journal":{"name":"Journal of Ocular Pharmacology and Therapeutics","volume":" ","pages":"281-289"},"PeriodicalIF":1.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144029106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Understanding Individual Intraocular Pressure Response to Treatment with Latanoprost and Timolol. 了解个体眼压对拉坦前列素和替莫洛尔治疗的反应。

IF 1.9 4区医学

Journal of Ocular Pharmacology and Therapeutics Pub Date : 2025-06-01 Epub Date: 2025-04-14 DOI: 10.1089/jop.2024.0112

Jeremy C Reitinger, David M Reed, Cameron Peres, Shan Fan, Vikas Gulati, Arash Kazemi, Arthur J Sit, Sayoko E Moroi, Carol B Toris

{"title":"Understanding Individual Intraocular Pressure Response to Treatment with Latanoprost and Timolol.","authors":"Jeremy C Reitinger, David M Reed, Cameron Peres, Shan Fan, Vikas Gulati, Arash Kazemi, Arthur J Sit, Sayoko E Moroi, Carol B Toris","doi":"10.1089/jop.2024.0112","DOIUrl":"10.1089/jop.2024.0112","url":null,"abstract":"Purpose: To identify reasons for variable intraocular pressure (IOP) responses to latanoprost and timolol in healthy volunteers and to generate the control group as part of Eye Dynamics and Engineering Network. Methods: In this multicenter, randomized, crossover study (NCT01677507), both eyes of 106 healthy subjects (212 eyes) were treated with latanoprost or timolol for 7 days, with a 6-week washout between treatments. Ocular biometrics, tonometry, and aqueous humor dynamics (AHD) were assessed at baseline and day 8 of each treatment. Subjects were divided into responders and nonresponders using cutoffs of >15% or >10% IOP reduction. Treatment effects and correlations were analyzed with paired t-tests. Results: More subjects responded to latanoprost (54%) than timolol (27%) at >15% cutoff (p < 0.01). Responders had higher mean baseline IOP than nonresponders for both drugs at both cutoffs (p < 0.01). Among timolol nonresponders (n = 56), 39% responded to latanoprost in both eyes, 20% in one eye, and 41% in neither. Among latanoprost nonresponders (n = 31), 13% responded to timolol in both eyes, 13% in one eye, and 74% in neither. Latanoprost increased uveoscleral outflow, while timolol reduced aqueous flow and outflow facility. Low baseline uveoscleral outflow was associated with latanoprost response. Conclusions: Higher baseline IOP predicted better responses to both drugs. Higher baseline uveoscleral outflow predicted nonresponse to latanoprost. No AHD differences were linked to the timolol response. Timolol nonresponders were often responsive to latanoprost, but not vice versa.","PeriodicalId":16689,"journal":{"name":"Journal of Ocular Pharmacology and Therapeutics","volume":" ","pages":"251-258"},"PeriodicalIF":1.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144014038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0